Get the Stockscreener App
7.03
2.50%
-0.18
After Hours:
7.15
0.12
+1.71%
Kala Bio Inc stock is traded at $7.03, with a volume of 9,199.
It is down -2.50% in the last 24 hours and up +3.84% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$7.21
Open:
$7.25
24h Volume:
9,199
Relative Volume:
0.16
Market Cap:
$42.82M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.5638
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+1.15%
1M Performance:
+3.84%
6M Performance:
+21.21%
1Y Performance:
-8.94%
1-Day Range:
$6.91
$7.2699
1-Week Range:
$6.5101
$7.30
52-Week Range:
$4.21
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
7.03 | 42.82M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Kala Bio appoints new interim CEO amid leadership shuffle - MSN
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - TradingView
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - The Manila Times
What Will KALA BIO Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN
Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - The Manila Times
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
KALA BIO's (KALA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Kala Bio Inc (NASDAQ: KALA) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
KALA BIO says CEO Mark Iwicki resigns - MSN
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Lee joins Lycia as CMO - BioCentury
Kala Bio announces CEO departure, appoints interim leader By Investing.com - Investing.com Nigeria
Kala Bio appoints new interim CEO amid leadership shuffle By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Chefs' Warehouse, Aptose Biosciences, Electromed - TradingView
Stock Market Today: Dow Jones tumbles 400 points as US inflation surges to 3%, S&P 500 and Nasdaq also slide amid Fed rate cut concerns - MSN
Stock Market Today: Dow Jones tumbles 400 points as US inflation surges to 3%, S&P 500 and Nasdaq also sli - The Economic Times
Stock market news: Spire Global -52.49%, Atomera -38.61% among biggest losers during midday trading - Business Upturn
Dow Drops More Than 400 Points After CPI Data - Schaeffers Research
Kala Bio Chief Executive Mark Iwicki Resigns; Shares Fall -February 12, 2025 at 11:59 am EST - Marketscreener.com
Kala Bio tumbles after CEO resignation - TradingView
Stock market today: Spire Global -50.98%, KALA BIO -32.54% among biggest losers in early trading - Business Upturn
Wall Street Today: Dow Jones drops 400 points as US Inflation rises 50 bps to 3% YoY, dimming hopes for Fed rate cuts - Mint
KALA BIO, Inc. Announces Chief Executive Officer Changes -February 12, 2025 at 08:00 am EST - Marketscreener.com
Kala Bio announces CEO departure, appoints interim leader - Investing.com
KALA BIO Announces Chief Executive Officer Transition - The Manila Times
Leadership Shake-Up at KALA BIO: New CEO Takes Helm Before Crucial Phase 2b Eye Treatment Results - StockTitan
KALA BIO (NASDAQ:KALA) and Prothena (NASDAQ:PRTA) Financial Survey - Defense World
Avis Budget CEO Joe Ferraro to Step Down, Brian Choi Named Successor - MSN
Katoro Gold announces general meeting and office move - MSN
Kala Pharma Catches Investors' Eye, Stock Hits New High - RTTNews
Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Rises By 19.1% - MarketBeat
Guardian Revival Names CEO - MSN
KALA stock soars to 52-week high, reaching $8.81 - MSN
KALA stock soars to 52-week high, reaching $8.81 By Investing.com - Investing.com Australia
ED Attaches ₹79.78 Crore Assets In Sharon Bio-Medicine’s ₹220 Crore Bank Fraud Case - Free Press Journal
Atara stock extends losses on FDA clinical hold (ATRA:NASDAQ) - Seeking Alpha
Ramesh Lal Kala , IND candidate bio : Assets , Total Income , Liabilities , Criminal Cases and other details. - The Hindu
KALA BIO Announces $10.75 Million Private Placement Agreement - WilmerHale
Kala Bio executive Todd Bazemore sells $15,206 in stock By Investing.com - Investing.com Australia
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):